|
An important milestone has been reached for our funding programme, as we have signed this month the contract of the 50th study funded ! We would like to thank all chief investigators and their teams who are running those studies, and we hope to fund many other exciting studies in the future ! The autumn has been occupied with the first steps of the selection process for the 15 study proposals we received in the investigator-led call 2022. We would like to express our gratitude to all committee reviewers (from Prioritisation Group, Panel or Trials Board) who made time to review and comment on the proposals. The BeNeFIT-3 call, in collaboration with the Netherlands, also opened in October and is still open until February 7th 2023. We are happy to share with you that results have been recently published for the Big Bird study and for the BeNeductus study (see section publication). Congratulations to those chief investigators and their teams for having reached the end of a long journey! We would like to take this opportunity to wish you a very happy festive season and good health and happiness for 2023. KCE Trials team |
Funding Opportunities
|
CALL BeNeFIT-3 is Open for applications The third BeNeFIT call, in collaboration with ZonMw, is open for applications. Joint research teams from Belgium and the Netherlands are able to submit an application. The call is open since October and will be closed on February 7th 2023. All information necessary to apply is available on the call webpage. PLEASE NOTE: during the weekend of 27-30 January 2023, the 'MyZonMw' system’ will not be accessible due to an update. We advise you to take this into account when submitting your application. |
Progress in funded studies
We are happy to announce the following important milestones have been reached in the trials below:
|
SAUNA Contract signed |
|
The SAUNA trial will investigate the efficacy of continued somatostatin analogues treatment upon disease progression in patients with non-functional, well-differentiated grade gastroenteropancreatic neuroendocrine tumours. 270 participants will be recruited in Belgium and the Netherlands.The study has been funded under the BeNefit-2 call. The sponsor of the study is UZA, Dr Marc Peeters is the chief investigator. Erasmus MC collaborates with UZA. |
|
PERSUADER Contract signed |
The PERsuaDER study is a randomised, controlled, open-label, multicentre trial, including 853 patients with primary resectable esophageal carcinoma planned for transthoracic esophagectomy. In these patients the effect of selective digestive decontamination (SDD) on reducing postoperative pneumonia and other infectious complications, anastomotic leakage and mortality after surgery will be studied.The study has been funded under the BeNefit-2 call. RadbouduMC is the sponsor of the study, Dr Hans van Veer (UZL) is coordinating the study for Belgium. | |
|
ALIVE Contract signed |
The ALIVE study will evaluate the effectiveness of Attachment Based Family Therapy (ABFT) compared to treatment as usual in suicidal young adults. The Belgian national coordinator is Prof. Guy Bosmans from KU Leuven. 138 participants will be randomized across 13 sites in Belgium and in the Netherlands.The study has been funded under the BeNefit-2 call. |
|
|
CASES Contract signed |
The CASES study compares Carotid Artery Stenting during Endovascular treatment of acute ischemic Stroke (CASES) versus deferred treatment of carotid artery stenosis in 600 patients with acute ischemic stroke due to proximal intracranial arterial occlusion and an ipsilateral cervical carotid artery stenosis of more than > 50% and of presumed atherosclerotic origin, who are eligible for EVT. The study has been funded under the BeNefit-2 call. UMC Groningen is the sponsor and Prof Dr Robin Lemmens (UZL) will coordinate the study for Belgium. |
|
|
PEPPER Contract signed |
The PEPPER study aims to determine the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients. The chief investigator is Prof. Dr. Tack from UZ Leuven. 609 participants will be recruited across 75 GPs in Belgium. 6 academic centres in general medicine will collaborate to this study. | |
|
SOPRANO FPI |
The SOPRANO trial compares two strategies to administer biological treatments to prevent postoperative endoscopic disease recurrence in Crohn's disease. The chief investigator is Prof. Dr. Ferrante from UZ Leuven. 352 participants will be included in this study across 24 sites. This study is also one of the first Belgian studies submitted through the CTIS, the new European platform for approval of clinical trials on drugs. |
The KCE Trials complete portfolio comprises 50 studies. more info>>
Impact
The latest scientific publications are presented below, and links to all publications can be found on the last tab of our dynamic dashboards.
More than 23 000 participants have been recruited so far in KCE funded trials!
Check our dynamic dashboard for real-time recruitment data for all KCE Trials funded studies
